Compounded Semaglutide in 2026: What It Is, Is It Legal, and Is It Safe

Quick answer

As of September 26, 2026, compounded semaglutide is a preparation that contains semaglutide, prepared by a state-licensed 503A compounding pharmacy under an individual prescription from a US-licensed physician. It is not FDA-approved as a final product and is not a generic version of, or interchangeable with, any brand-name medication. Through US telehealth it is typically priced as one all-in monthly amount; the full 2026 numbers are in our compounded semaglutide cost guide.

As of September 2026 it remains lawfully available under section 503A (21 U.S.C. 353a). The FDA's shortage-linked enforcement discretion for 503A pharmacies ended on April 24, 2025; since then the ordinary 503A rules apply in full: every prescription is for an identified individual patient, and the physician documents the change that makes a compounded preparation appropriate for that patient.

What is compounded semaglutide?

Compounded semaglutide contains semaglutide, prepared by a licensed compounding pharmacy for an individual patient. It is not FDA-approved as a final product and is not a generic version of, equivalent to, or interchangeable with any FDA-approved medication.

Under 21 U.S.C. 353a, a pharmacy may compound a drug product "for an identified individual patient based on the receipt of a valid prescription order." As the FDA puts it, "state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities." The other pathway, 21 U.S.C. 353b, covers FDA-registered outsourcing facilities (503B); see 503A pharmacies versus 503B outsourcing facilities.

What "not FDA-approved" means, in the FDA's words. The FDA's compounding Q&A states: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." The same page says a compounded drug is not a generic: "A generic drug is approved by FDA under 505(j) of the FD&C Act," with therapeutic equivalence established, "while a compounded drug is not approved by FDA." What that means for a patient is covered in is compounded semaglutide FDA approved?.

Is compounded semaglutide legal in the United States?

Yes, within a defined regulatory framework. Under section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies may prepare medication for an individual patient based on a valid prescription from a licensed physician who has determined it is clinically appropriate for that specific patient. These pharmacies must:

• Hold active state pharmacy licenses in the states they serve, under state board of pharmacy oversight
• Compound to United States Pharmacopeia (USP) standards (USP 795 and 797)
• Dispense only against patient-specific prescriptions, not in bulk
• Employ licensed pharmacists who oversee every preparation

Since the FDA's shortage-linked enforcement discretion for 503A pharmacies ended on April 24, 2025, compounding rules have tightened: compounded semaglutide may not be simply a copy of the brand product, and the prescribing physician must document the clinical reason it is appropriate for the individual patient. A legitimate provider works only with pharmacies and physicians that follow this framework.

At Majesta Health, prescribing is done by US-licensed physicians through MD Integrations, our telehealth provider group partner, and the state-licensed 503A pharmacy that prepares your prescription is named on your label.

Can my doctor prescribe compounded semaglutide, and can any pharmacy make it? A physician licensed in your state may prescribe it when clinically appropriate for you. Only a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility may compound it.

Can you still get compounded semaglutide in 2026, after the shortage ended?

Yes. Compounded semaglutide is still available from a state-licensed 503A pharmacy on a patient-specific prescription; what ended in 2025 was a temporary FDA enforcement policy tied to the shortage, not section 503A itself.

The FDA's own statement gives the timeline: on April 24, 2025 a federal district court denied the plaintiffs' motion for a preliminary injunction in Outsourcing Facilities Association v. FDA, and the FDA stated: "For a state-licensed pharmacy or physician compounding, dispensing or distributing semaglutide injection products under section 503A of the FD&C Act, the period of enforcement discretion (described below) has ended." Outsourcing facilities under section 503B had until May 22, 2025.

What governs today is the ordinary 503A rule. Section 353a(b)(1)(D) bars compounding "regularly or in inordinate amounts" drug products that are "essentially copies of a commercially available drug product." Section 353a(b)(2) defines the exception: a preparation "in which there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner." In plain words, the physician documents what is different for you and why it matters clinically; price alone is not a clinical reason.

Is the FDA banning compounded semaglutide? No. The FDA has not banned 503A compounding of semaglutide. Its concerns page, current as of September 1, 2026, says a compounded drug "might be appropriate if a patient's medical need cannot be met by an FDA-approved drug," and lists what it acts against: salt forms, fraudulent labels and illegal sellers, covered below. The ordering side is in getting compounded semaglutide online.

How compounded semaglutide works

Semaglutide, the molecule in the compounded preparation, is a GLP-1 receptor agonist; FDA labeling for the approved products describes the mechanism: it mimics glucagon-like peptide-1, a hormone the gut releases in response to food. It slows gastric emptying so food stays in the stomach longer, acts on appetite centers in the brain to reduce the drive to eat between meals, and improves insulin secretion in response to glucose.

No clinical trials have been conducted on compounded semaglutide itself, so we do not quote efficacy figures for it. Your prescribing physician sets the dose; the schedule is on the pharmacy label and set by the prescriber. Individual results may vary. The studied route is injection; Majesta Health does not offer compounded oral or sublingual versions, and our guide to oral and sublingual GLP-1 forms explains why. The pharmacology is in the science behind GLP-1 and semaglutide.

Is compounded semaglutide safe? What the FDA has flagged

Safety in practice depends on three things: pharmacy quality, physician evaluation, and honest patient disclosure. Compounded semaglutide prepared under USP 795 and 797 by a state-licensed pharmacy is still not FDA-approved as a final product; the agency "does not review compounded drugs for safety, effectiveness or quality before they are marketed."

The FDA's concerns page names the problems it has seen in the compounded GLP-1 market. Each is a question for a provider:

• Salt forms. "These salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs," and the FDA is "not aware of any lawful basis for their use in compounding."
• Dosing errors. A 2024 FDA alert linked adverse-event reports to patients unfamiliar with drawing medication from a vial into a syringe and confused between different units of measurement, and "encourages health care providers and compounders to provide patients with the appropriate syringe size for the intended dose and counsel patients on how to measure the intended dose using the syringe." A clear label, the right syringe and a reachable physician are the safeguards.
• Multi-dose vials. For a multidose vial containing sterile compounded GLP-1 medication, FDA recommends: "Discard the vial within 28 days after the first use, even if medication remains in the vial. Do not continue using medication from the vial after 28 days, even if instructions from the compounder say the medication can be used for longer than 28 days." Check the pharmacy label's beyond-use date and storage directions as well; the FDA recommendation does not extend an earlier limit.
• Storage during shipping. "FDA has received complaints that certain compounded GLP-1 drugs have arrived warm or with inadequate ice packs to keep the drug at recommended storage temperatures." The FDA recommends not using an injectable GLP-1 drug that arrives warm.
• Fraudulent labels. "In some cases, the compounding pharmacies identified on the labels of the products do not exist," and in others a real pharmacy's name was used on a product it did not make.
• Ingredient imports. The FDA "has established a green list import alert (66-80) to help stop GLP-1 active pharmaceutical ingredients (APIs) that have potential quality concerns from entering the U.S. supply chain."

Adverse event reports. As of May 31, 2026 the FDA had received 990 adverse event reports associated with compounded semaglutide. The FDA's caveat belongs next to that number: "It is not always possible to determine if the adverse event directly resulted from use of the drug or if other factors may have contributed to these adverse events." The count is not a safety comparison between compounded and approved products; the FDA asks patients and clinicians to report problems to MedWatch.

How long a preparation stays usable is covered in how long compounded semaglutide is good for.

Who is a candidate for compounded semaglutide, and who is not

A licensed physician decides candidacy from your complete medical history; the framework below is what physicians screen against, not a promise of eligibility.

The population physicians screen against. FDA prescribing information for semaglutide weight-management products describes the indicated adult population as adults with obesity, or "adults with overweight in the presence of at least one weight-related comorbid condition." See how to qualify for compounded semaglutide and the BMI calculator.

Contraindications named in the class labeling. FDA prescribing information for semaglutide products carries a boxed warning on thyroid C-cell tumors, based on rodent findings, and lists these contraindications:

• A personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• A prior serious hypersensitivity reaction to semaglutide or to any of the preparation's excipients

Warning categories a physician screens for. The same labeling lists acute pancreatitis, acute gallbladder disease, hypoglycemia when combined with insulin or insulin secretagogues, acute kidney injury from volume depletion, severe gastrointestinal adverse reactions including severe gastroparesis, hypersensitivity reactions, diabetic retinopathy complications in people with type 2 diabetes, heart-rate increase, and pulmonary aspiration during general anesthesia or deep sedation. On pregnancy the labeling is direct: "Weight loss offers no benefit to a pregnant patient and may cause fetal harm." Pregnancy, planned pregnancy, breastfeeding, planned surgery or sedation, type 1 diabetes and any eating-disorder history are therefore things to tell the physician before treatment. Disclose everything, including supplements.

What does a legitimate telehealth process for compounded semaglutide look like?

A legitimate process has a licensed physician between you and the pharmacy at every step. At Majesta Health the flow is five steps:

1. Medical assessment. Confirm your state, goals, and medical history. Louisiana and Mississippi are waitlist-only; residents there can join the waitlist and we will email you when care opens.
2. Telehealth consent. Informed consent is required before any clinical evaluation.
3. Physician review. A physician licensed in your state reviews your file, with a phone or video visit where your state's rules or the physician require it. If treatment is appropriate, the physician writes the prescription; if not, the physician explains why. Nothing is charged unless a physician approves treatment.
4. Pharmacy fills the prescription. A state-licensed 503A pharmacy prepares your patient-specific prescription and names itself on the label.
5. Shipping and ongoing care. Your medication ships to your door, and your care team stays reachable for questions and side-effect support.

The full walkthrough is in how to get compounded semaglutide; semaglutide near me explains why availability follows licensing, not distance.

Verify the physician

Every state medical board publishes a license lookup. California's runs through the Department of Consumer Affairs search, a tool "to verify a license issued by the Department of Consumer Affairs (DCA) for the professions listed under license type." The NPI Registry run by CMS confirms a clinician's National Provider Identifier. See how to verify a doctor's license.

Verify the pharmacy

Ask which pharmacy will fill your prescription, then look it up on that state's board of pharmacy site. California's board states that "information on the board's Web site can be accepted as verification of a license, per Business and Professions Code section 4106"; every state board has a comparable search, and the FDA's BeSafeRx campaign "helps consumers learn about how to safely buy prescription medicines online." The name on your label should match the pharmacy you looked up.

Questions to ask your physician

• Which pharmacy will compound my prescription, and in which state is it licensed?
• What form of semaglutide does the pharmacy use, and how is the preparation tested?
• What is the clinical reason a compounded preparation is appropriate for me, and what would make you stop treatment?
• What will my label say, what syringe will I use, and who answers my questions after the medication arrives?

Availability is set by licensing in both directions: Majesta Health plans care in 48 states, with Louisiana and Mississippi waitlist-only; the state availability index names each state's medical board and rules, and the help center covers the practical questions.

Compounded semaglutide provider red flags

The FDA's telehealth red flags for consumers, in summary: walk away from a company that:

• claims its compounded drug is no different from an FDA-approved drug
• offers medicine at deep discounts or prices that seem too good to be true
• sends medicine that looks different from what was pictured, or arrives damaged or without instructions for use
• does not require a screening and prescription by a licensed doctor before providing medicine
• does not have a licensed doctor available to answer questions after you receive your medication
• makes spelling errors on the label or provides incorrect addresses of the pharmacy
• includes a pharmacy name on the label that you think might be fraudulent

Our own list adds: promises of specific pounds lost; marketing the medication as FDA-approved or hiding the compounded status; refusing to name the compounding pharmacy; prices that seem too good to be true, with no explanation of what they include; and no business address or phone number.

Five things to verify before you pay: a licensed physician reviews your case, not a chatbot; the pharmacy is named, state-licensed, and holds LegitScript pharmacy certification, verifiable in LegitScript's public registry; pricing is transparent; supervision is ongoing; and testing practices are documented. What the LegitScript mark means is in what LegitScript certification is.

What are the side effects of compounded semaglutide?

No separate trials exist for the compounded preparation, so the categories below come from FDA labeling for the approved semaglutide products and describe the molecule, not any compounded product; a compounded preparation can also carry the preparation-specific risks the FDA flags above. We list categories by name and quote no frequencies, since the labeling's frequencies were measured for the approved product.

• Gastrointestinal: nausea, vomiting, diarrhea or constipation, reflux, abdominal discomfort, the most commonly reported group
• Injection site: injection site reactions where you inject
• Gallbladder: acute gallbladder disease, including gallstones
• Pancreas: acute pancreatitis, which the labeling says has been observed in patients treated with GLP-1 receptor agonists
• Blood sugar: hypoglycemia, especially with insulin or insulin secretagogues
• Kidney: acute kidney injury from volume depletion after severe vomiting or diarrhea
• Hypersensitivity: allergic reactions, including serious ones
• Eyes: diabetic retinopathy complications in people with type 2 diabetes
• Heart rate: an increase in resting heart rate
• Thyroid: the boxed-warning topic of thyroid C-cell tumors, seen in rodents; the reason MTC and MEN 2 are contraindications

Contact your prescribing physician for symptoms that persist or are severe, and seek emergency care for symptoms suggesting pancreatitis, a severe allergic reaction, severe dehydration, or severe hypoglycemia. Management tips are in our semaglutide side effects guide.

Compounded semaglutide vs other GLP-1 options

The honest comparison is about approval status, form, and supervision.

The FDA-approved semaglutide product comes with FDA review before marketing, a manufacturer-made device and labeling, and FDA post-market oversight; a compounded preparation has none of those, and no head-to-head trial compares the two.

Compounded tirzepatide. Tirzepatide is a dual GIP and GLP-1 receptor agonist, acting on two gut hormone pathways instead of one. At Majesta Health it is the Performance plan, and whether it fits your history is the physician's call; see our compounded tirzepatide guide.

Sublingual semaglutide. A troche offered by some providers; Majesta Health does not offer it, because the injectable route is the one with a clinical evidence base.

Compounded semaglutide at Majesta Health: plans, pricing and how to start

Majesta Health's compounded semaglutide program has two physician-guided plans; the listed price is the whole price.

• Essential (compounded semaglutide injection): $179 first month, then $299 every 30 days. A $20 medical consultation fee is included in your first month, collected on a pass-through basis to the prescribing provider where applicable. Cancel anytime, no fees.
• Performance (compounded tirzepatide injection): $339 first month, then $439 every 30 days.

Both plans include the physician review, the medication, shipping, and ongoing support. A licensed physician reviews your file and decides; nothing is charged unless a physician approves treatment. Full details are on our pricing page.

What a monthly price should include. Physician review, the medication, shipping, ongoing physician access, and no enrollment or cancellation fees; if any of those is a separate line, the advertised price is not the price. What drives the monthly price is in our compounded semaglutide cost guide; how several providers publish their prices, each with its source and the date it was read, is compared in compounded GLP-1 prices compared.

How to start. Join the early access list and we will email you when enrollment opens. A licensed physician then reviews your file; medication is prescribed only if the physician determines it is appropriate for you.

What the primary sources say

• Legal Information Institute, Cornell Law School, 21 U.S.C. 353a(a) Pharmacy compounding (accessed September 26, 2026): "Sections 351(a)(2)(B), 352(f)(1), and 355 of this title shall not apply to a drug product if the drug product is compounded for an identified individual patient based on the receipt of a valid prescription order"
• Legal Information Institute, Cornell Law School, 21 U.S.C. 353a(b)(2), what the term essentially a copy does not include (accessed September 26, 2026): "does not include a drug product in which there is a change, made for an identified individual patient, which produces for that patient a significant difference, as determined by the prescribing practitioner, between the compounded drug and the comparable commercially available drug product"
• U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers (accessed September 26, 2026): "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."
• U.S. Food and Drug Administration, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (accessed September 26, 2026): "Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy."
• MedlinePlus, U.S. National Library of Medicine, Semaglutide Injection (AHFS drug information), Important Warning (accessed September 29, 2026): "Tell your doctor if you or anyone in your family has or has ever had thyroid tumors, thyroid cancer, or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2; condition that causes tumors in more than one gland in the body). If so, your doctor will probably tell you not to use semaglutide injection."

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider. Compounded medications are not FDA-approved as final products. Medication is prescribed only if a licensed physician determines it is appropriate. Prices are Majesta Health's published prices as of September 2026 and are subject to change. Individual results may vary.